BioWorld

Aug. 24, 2006

Ablynx €40M Round Notable Among European Financings

In one of the largest European private placements conducted this year, Ablynx NV raised €40 million (US$51.2 million) in a Series C round to drive more of its programs into preclinical and clinical development. (BioWorld Today) Read More

Theravance's Phase III Data: Non-Inferior To Vancomycin

Debate Over Whether New Stem Cell Science Will Change Policy

Kemia Adds $31M In Series C, Reports Positive Phase I Data

Theratechnologies SPA Aligns Second TH9507 Pivotal Study

Other News To Note

Clinic Roundup

U.S. Patent Disclosures

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...